CJC-1295 Ipamorelin

$79

CJC-1295 (No DAC; Modified GRF 1–29) + Ipamorelin is a research peptide blend combining a GHRH analogue and a selective ghrelin receptor agonist. Experimental literature evaluates its coordinated effects on growth hormone axis signaling pathways. Laboratory models investigate receptor-level interactions and endocrine feedback mechanisms under controlled conditions without implying human outcomes.

  • $79 / month — Save 10%

Description

What It Is CJC-1295 (No DAC; Modified GRF 1–29) + Ipamorelin is a laboratory-formulated peptide blend combining a growth hormone–releasing hormone (GHRH) analogue with a selective growth hormone secretagogue studied in research models of endocrine signaling.
What It’s Derived From CJC-1295 (No DAC) is derived from a truncated and stabilized form of endogenous GHRH designed for receptor-specific interaction. Ipamorelin is a synthetic peptide engineered to selectively bind the ghrelin receptor (GHSR-1a) and model growth hormone–related signaling pathways.
What Research Focuses On Research evaluates this combination in preclinical and in vitro models examining coordinated activation of GHRH receptors and ghrelin receptors, downstream cAMP/PKA and Gq/11-linked signaling pathways, pulsatile growth hormone axis dynamics, and hypothalamic–pituitary regulatory mechanisms under controlled laboratory conditions.

Additional information

Weight 0.0125 lbs
Dimensions 0.625 × 0.625 × 1.5 in
Dosage

10mg

Reviews

There are no reviews yet.

Be the first to review “CJC-1295 Ipamorelin”

Your email address will not be published. Required fields are marked *